News on Medial

IAN Angel Fund leads Rs 4 Cr in Seed round in Famyo

EntrackrEntrackr ยท 1m ago
IAN Angel Fund leads Rs 4 Cr in Seed round in Famyo
Medial

Famyo, a Bengaluru-based kidsโ€™ lifestyle brand that transforms everyday essentials into cool, collectible products, has raised Rs 4 crore in a seed funding round led by IAN Angel Fund. Other investors include Shivali Vij, Deepank Kumar, Pratik Mathurkar, and Uday Sodhi, with participation from The Chennai Angels, Stoffer Norden, and other strategic backers. The proceeds will be used to develop proprietary IP, expand character design, build influencer and performance-led marketing engines, and strengthen talent across product, growth, and supply chains. Founded by Karishma Seetharaman and Ritvik Raj, Famyo is turning everyday items such as blankets, towels, pouches, and school gear into design-first, collectible-led products anchored in original characters and themes. Its offerings like glow-in-the-dark blankets, poncho towels, and character-themed accessories, blend playful design with safety and premium quality, addressing the dual needs of kids seeking fun and parents demanding reliability. The brand claims to have already achieved an ARR of over Rs 12 crore and is growing 40% quarter-on-quarter, with strong resonance among both children and parents. Over the next 12โ€“24 months, Famyo aims to scale 4x, expand its IP portfolio, and launch new collectible-driven seasonal drops and collaborations.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr ยท 2m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IANโ€™s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditionsโ€”ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.